In the phase 3 AFIRM trial, natalizumab (Tysabri®, Biogen Idec) significantly reduced annualized relapse rate and the risk of sustained disability progression over 2 years (Table 3).

**RESULTS**

Anti-JCV antibody index and PML

The anti-JCV antibody index was calculated as the optical density (OD) value of treatments divided by the assay calibrator. The anti-JCV antibody index was correlated with the risk of PML in patients who developed PML (Figure 2A).

- 24/25 (96%) of natalizumab-treated MS patients who developed PML had an anti-JCV antibody index >1.5.
- Approximately 4% of patients who tested anti-JCV antibody negative at baseline fell below a range of anti-JCV antibody index thresholds.

Longitudinal stability of anti-JCV antibody index

- Anti-JCV antibody index was calculated as the optical density (OD) value of treatments divided by the assay calibrator. The anti-JCV antibody index was correlated with the risk of PML in patients who developed PML (Figure 2A).

**OBJECTIVES**

- To assess the association of anti-JCV antibody index with PML risk in natalizumab-treated patients.
- To determine whether the anti-JCV antibody index threshold from the Phase 3 AFIRM trial would also be applicable in the REALIS study and postmarketing data.

**METHODS**

- Anti-JCV antibody index was calculated as the optical density (OD) value of treatments divided by the assay calibrator. The anti-JCV antibody index was correlated with the risk of PML in patients who developed PML (Figure 2A).
- Approximately 4% of patients who tested anti-JCV antibody negative at baseline fell below a range of anti-JCV antibody index thresholds.

**DISCUSSION**

- The anti-JCV antibody index is a useful tool for predicting PML risk in patients with natalizumab. The anti-JCV antibody index is a useful tool for predicting PML risk in patients with natalizumab.
- The anti-JCV antibody index is a useful tool for predicting PML risk in patients with natalizumab.

**REFERENCES**


**CONCLUSIONS**

- Anti-JCV antibody index thresholds remain highly predictive of PML risk in patients treated with natalizumab.
- The anti-JCV antibody index thresholds in the REALIS study are consistent with those in the AFIRM trial.
- The anti-JCV antibody index thresholds in the REALIS study are consistent with those in the AFIRM trial.

**DISCLOSURES**

All authors are employees of Biogen Idec.